Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 42 of 42 matching drugs for DDR2 — including drugs targeting any of its 47 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab DDR2 Direct 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) DDR2 Direct 4
regorafenib DDR2 Direct yes 2
regorafenib, laboratory biomarker analysis DDR2 Direct 2
gemcitabine, oxaliplatin, imatinib DDR2 Direct 1
imatinib, irinotecan, carboplatin DDR2 Direct 1
regorafenib, lomustine DDR2 Direct 1
regorafenib, nivolumab, capeox, folfox regimen DDR2 Direct 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil DDR2 Direct 1
regorafenib, temozolomide DDR2 Direct 1
temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 DDR2 Direct 1
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3CB SSL via PIK3CB 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3CG SSL via PIK3CG 3
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib DDR1 SSL via DDR1 2
biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging PIK3CB SSL via PIK3CB 1
biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging PIK3CG SSL via PIK3CG 1
biopsy, biospecimen collection, copanlisib, radiologic examination PIK3CB SSL via PIK3CB 1
biopsy, biospecimen collection, copanlisib, radiologic examination PIK3CG SSL via PIK3CG 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
gemcitabine, oxaliplatin, imatinib DDR1 SSL via DDR1 1
imatinib, irinotecan, carboplatin DDR1 SSL via DDR1 1
afatinib dimaleate EGFR SSL via EGFR yes 0
cetuximab EGFR SSL via EGFR yes 0
duvelisib PIK3CG SSL via PIK3CG yes 0
erlotinib hydrochloride EGFR SSL via EGFR yes 0
lapatinib EGFR SSL via EGFR yes 0
lapatinib ditosylate EGFR SSL via EGFR yes 0
necitumumab EGFR SSL via EGFR yes 0
neratinib EGFR SSL via EGFR yes 0
neratinib maleate EGFR SSL via EGFR yes 0
nilotinib DDR1 SSL via DDR1 yes 0
nilotinib hydrochloride monohydrate DDR1 SSL via DDR1 yes 0
osimertinib mesylate EGFR SSL via EGFR yes 0
panitumumab EGFR SSL via EGFR yes 0
regorafenib EGFR SSL via EGFR yes 0
vandetanib EGFR SSL via EGFR yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.